Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Stryker Corporation — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.37, while Stryker Corporation trades at $309.94 (market cap $120.60B). The key difference: Stryker Corporation pays a 1.12% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Stryker Corporation is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEI | SYK | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $120.72 | $403.53 |
52-Week Low | $116.45 | $282.58 |
Market Cap | — | $120.60B |
Enterprise Value | — | $132.36B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.76, down 0.19% with a bearish technical signal from moving averages. The ETF focuses on intermediate-term U.S. Treasury bonds, offering lower volatility compared to corporate bond alternatives. Recent news highlights institutional selling by AlTi Global Inc. and competitive pressure from Vanguard's lower-cost bond ETFs.
The outlook remains cautious amid Federal Reserve uncertainty and rising inflation concerns. While Treasury ETFs provide safety during market stress, IEI faces headwinds from potential rate hikes and stronger-yielding alternatives. Key risks include interest rate sensitivity and investor preference for higher-yield bond options in the current environment.
Stryker (SYK) trades at $319.14, down 0.23% with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust margins. Recent news highlights Mako RPS launch expansion in robotic surgery, while Q1 2026 earnings missed expectations due to a temporary cyber disruption, though full-year guidance remains unchanged.
Outlook remains positive with 74% analyst buy ratings and a $388.44 consensus price target implying 22% upside. Key risks include competitive pressures and execution challenges from recent cybersecurity issues. The stock presents a growth opportunity in med-tech innovation, trading below historical valuation multiples with healthy cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
